Nida Laurin, MD
Neurology · Scottsdale, AZNPI 1306887963
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $701,683 of the $968,918 with a category attached, or 72.4%. It is spread thinly across 53 manufacturers, the largest accounting for just 20.4%. Among neurology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,565 payments — averaging $619.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- EMD Serono, Inc.$198K
- Biogen$151K
- Sanofi$149K
- Lilly USA, LLC$115K
- Amgen$112K
- AstraZeneca$39K
- plus $204K from 47 others
Across 145 payments — averaging $9236.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$556K
- Sanofi$241K
- UCB SA$223K
- AbbVie$157K
- EMD Serono, Inc.$54K
- Amgen$43K
- plus $66K from 5 others
What the payments were for
- Consulting fees$143,43615%
- Speaking & faculty fees$701,68372%
- Travel & lodging$67,5347%
- Food & beverage$53,0205%
- Education$5130%
- Gifts$2,7330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$968,918 in reported general payments places this provider in the 95th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 25 | $237,227 |
| CopaxoneGlatiramer Acetate | 20 | $112,527 |
| IngrezzaValbenazine Tosylate | 12 | $101,443 |
| BafiertamMonomethyl Fumarate | 11 | $68,354 |
| Aimovig AutoinjectorErenumab-Aooe | 39 | $41,210 |
| Dalfampridine ErDalfampridine | 51 | $33,145 |
| Nurtec OdtRimegepant Sulfate | 12 | $22,495 |
| QuliptaAtogepant | 14 | $15,993 |
| Emgality PenGalcanezumab-Gnlm | 21 | $15,217 |
| BotoxOnabotulinumtoxina | 12 | $12,332 |
| Modafinil | 11 | $5,090 |
| Gabapentin | 192 | $4,380 |
| Entacapone | 19 | $2,529 |
| Teriflunomide | 39 | $2,417 |
| Memantine Hcl | 67 | $2,352 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $75 | $112,52720 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $17 | $101,44312 claims |
| AbbVieQulipta, Botox | $18,839 | $28,32626 claims |
| PfizerNurtec Odt | $957 | $22,49512 claims |
| Upsher-smith Laboratories LLCTopiramate | $14 | $61643 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 neurology providers in Arizona.
Other neurology in Scottsdale
- Dean WingerchukScottsdale$324K
- Amaal StarlingScottsdale$315K
- Virgilio Gerald EvidenteScottsdale$231K
- Brent GoodmanScottsdale$198K
- David SapersteinScottsdale$135K
- Maciej MrugalaScottsdale$97K
- Charles AdlerScottsdale$74K
- Jill RauScottsdale$59K
- Shyamal MehtaScottsdale$50K
- Jonathan CarterScottsdale$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.